首页|醒脑静注射液辅助治疗对老年轻型脑外伤患者近期及远期预后的影响

醒脑静注射液辅助治疗对老年轻型脑外伤患者近期及远期预后的影响

扫码查看
目的:探讨醒脑静注射液辅助治疗对老年轻型脑外伤患者近期及远期预后的影响.方法:选自茂名石化医院2020年1月—2023年12月收治的80例老年轻型脑外伤患者为研究对象,按照随机数字法分组,分为对照组(40例给予常规治疗+高压氧舱内压迫治疗)、观察组(40例在对照组的基础上联合醒脑静注射液治疗);比较两组治疗效果、NIHSS评分、MMSE评分、ADL评分、SF-36评分以及不良事件发生率.结果:相对于对照组,观察组治疗总有效率更高(P<0.05);相对于对照组,观察组治疗后NIHSS评分更低(P<0.05),观察组患者的MMSE评分、ADL评分以及SF-36评分更高(P<0.05);观察组患者的不良事件发生率低于对照组(P<0.05).结论:醒脑静注射液在老年轻型脑外伤患者治疗中的应用效果十分显著,具有很高的价值,可在未来临床中加以应用和推广.
Effect of Adjuvant Therapy of Xingnaojing Injection on Short-term and Long-term Prognosis of Senile Patients with Mild Brain Trauma
Objective:To investigate the effect of Xingnaojing injection adjuvant therapy on the short-term and long-term prognosis of elderly patients with mild brain injury.Methods:A total of 80 elderly patients with mild traumatic brain injury admitted to Maoming Petrochemical Hospital from January 2020 to December 2023 were selected as the study objects.They were divided into control group(40 cases received conventional treatment+hyperpressure oxygen chamber compression treatment)and observation group(40 cases received Xingnaojing injection treatment on the basis of the control group)according to random number method.The treatment effect,NIHSS score,MMSE score,ADL score,SF-36 score and incidence of adverse events were compared between the two groups.Results:Compared with the control group,the total effective rate of the observation group was higher(P<0.05).Compared with control group,NIHSS score of observation group was lower after treatment(P<0.05),MMSE score,ADL score and SF-36 score of observation group were higher(P<0.05).The incidence of adverse events in observation group was lower than that in control group(P<0.05).Conclusion:Xingnaojing injection has significant effect in the treatment of senile patients with mild traumatic brain injury,and has high value,which can be applied and promoted in the future clinic.

Xingnaojing InjectionSenile Mild Traumatic Brain InjuryEffectPrognosis

何春林

展开 >

茂名石化医院神经外科(广东茂名 525000)

醒脑静注射液 老年轻型脑外伤 效果 预后

茂名市科技计划项目

220412164551295

2024

黑龙江医药
黑龙江省药品审评认证中心

黑龙江医药

影响因子:0.597
ISSN:1006-2882
年,卷(期):2024.37(4)
  • 6